Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation

作者: Amy P.M. Finch , Jan Lubinski , Pål Møller , Christian F. Singer , Beth Karlan

DOI: 10.1200/JCO.2013.53.2820

关键词:

摘要: Purpose The purposes of this study were to estimate the reduction in risk of ovarian, fallopian tube, or peritoneal cancer in women with a BRCA1 or BRCA2 mutation after oophorectomy, by age of oophorectomy; to estimate the impact of prophylactic oophorectomy on all-cause mortality; and to estimate 5-year survival associated with clinically detected ovarian, occult, and peritoneal cancers diagnosed in the cohort. Patients and Methods Women with a BRCA1 or BRCA2 mutation were identified from an international registry; 5,783 women completed a baseline questionnaire and ≥ one follow-up questionnaires. Women were observed until either diagnosis of ovarian, fallopian tube, or peritoneal cancer, death, or date of most recent follow-up. Hazard ratios (HRs) for cancer incidence and all-cause mortality associated with oophorectomy were evaluated using time-dependent survival analyses. Results After an average follow-up period of 5.6 years, 186 women developed either ovarian (n = 132), fallopian (n = 22), or peritoneal (n = 32) cancer, of whom 68 have died. HR for ovarian, fallopian, or peritoneal cancer associated with bilateral oophorectomy was 0.20 (95% CI, 0.13 to 0.30; P < .001). Among women who had no history of cancer at baseline, HR for all-cause mortality to age 70 years associated with an oophorectomy was 0.23 (95% CI, 0.13 to 0.39; P < .001). Conclusion Preventive oophorectomy was associated with an 80% reduction in the risk of ovarian, fallopian tube, or peritoneal cancer in BRCA1 or BRCA2 carriers and a 77% reduction in all-cause mortality.

参考文章(17)
Kelly A. Metcalfe, Nida Mian, Melissa Enmore, Aletta Poll, Marcia Llacuachaqui, Sonia Nanda, Ping Sun, Kevin S. Hughes, Steven A. Narod, Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening Breast Cancer Research and Treatment. ,vol. 133, pp. 735- 740 ,(2012) , 10.1007/S10549-011-1941-0
A. Finch, K.A. Metcalfe, J.K. Chiang, L. Elit, J. McLaughlin, C. Springate, R. Demsky, J. Murphy, B. Rosen, S.A. Narod, The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation Gynecologic Oncology. ,vol. 121, pp. 163- 168 ,(2011) , 10.1016/J.YGYNO.2010.12.326
J LANCASTER, C BETHANPOWELL, N KAUFF, I CASS, L CHEN, K LU, D MUTCH, A BERCHUCK, B KARLAN, T HERZOG, Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecologic Oncology. ,vol. 107, pp. 159- 162 ,(2007) , 10.1016/J.YGYNO.2007.09.031
Amy Finch, Gareth Evans, Steven A Narod, None, BRCA carriers, prophylactic salpingo-oophorectomy and menopause: Clinical management considerations and recommendations Women's Health. ,vol. 8, pp. 543- 555 ,(2012) , 10.2217/WHE.12.41
Kelly A Metcalfe, Daphna Birenbaum‐Carmeli, Jan Lubinski, Jacek Gronwald, Henry Lynch, Pal Moller, Parviz Ghadirian, William D Foulkes, Jan Klijn, Eitan Friedman, Charmaine Kim‐Sing, Peter Ainsworth, Barry Rosen, Susan Domchek, Teresa Wagner, Nadine Tung, Siranoush Manoukian, Fergus Couch, Ping Sun, Steven A Narod, Hereditary Breast Cancer Clinical Study Group, International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer. ,vol. 122, pp. 2017- 2022 ,(2008) , 10.1002/IJC.23340
Amy Finch, Patricia Shaw, Barry Rosen, Joan Murphy, Steven A. Narod, Terence J. Colgan, Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers Gynecologic Oncology. ,vol. 100, pp. 58- 64 ,(2006) , 10.1016/J.YGYNO.2005.06.065
Pamela J. Paley, Elizabeth M. Swisher, Rochelle L. Garcia, S.Nicholas Agoff, Benjamin E. Greer, Ksenia L. Peters, Barbara A. Goff, Occult Cancer of the Fallopian Tube in BRCA-1 Germline Mutation Carriers at Prophylactic Oophorectomy: A Case for Recommending Hysterectomy at Surgical Prophylaxis Gynecologic Oncology. ,vol. 80, pp. 176- 180 ,(2001) , 10.1006/GYNO.2000.6071
R I Olivier, M van Beurden, M A C Lubsen, M A Rookus, T M Mooij, M J van de Vijver, L J van't Veer, Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up British Journal of Cancer. ,vol. 90, pp. 1492- 1497 ,(2004) , 10.1038/SJ.BJC.6601692
Andrea Eisen, Jan Lubinski, Jan Klijn, Pal Moller, Henry T. Lynch, Kenneth Offit, Barbara Weber, Tim Rebbeck, Susan L. Neuhausen, Parviz Ghadirian, William D. Foulkes, Ruth Gershoni-Baruch, Eitan Friedman, Gadi Rennert, Teresa Wagner, Claudine Isaacs, Charmaine Kim-Sing, Peter Ainsworth, Ping Sun, Steven A. Narod, Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study Journal of Clinical Oncology. ,vol. 23, pp. 7491- 7496 ,(2005) , 10.1200/JCO.2004.00.7138
John R. McLaughlin, Barry Rosen, Joel Moody, Tuya Pal, Isabel Fan, Patricia A. Shaw, Harvey A. Risch, Thomas A. Sellers, Ping Sun, Steven A. Narod, Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2 Journal of the National Cancer Institute. ,vol. 105, pp. 141- 148 ,(2013) , 10.1093/JNCI/DJS494